CTRI/2020/02/023237
Recruiting
Phase 4
An open label, multi-centric, prospective clinical trial to evaluate safety and efficacy of fixed dose combination of Montelukast 10 mg plus Acebrophylline SR 200 mg tablet in patients having bronchial asthma in India
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Sun Pharma Laboratories Limited
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Male or female patient with age 18 \- 65 years (both inclusive)
- •2\.Patient having confirmed diagnosis of asthma as per GINA 2018 guideline since at least 3 months prior to screening
- •3\.Patient having current sign/symptoms of asthma or need for SABA more than twice a week
- •4\.Patient who is suitable to take Montelukast and Acebrophylline as per GINA 2018 guideline
- •5\.Female patient of childbearing potential, willing to use effective contraception during the study and willing to undergo pregnancy test. Effective contraceptive include (e.g. barrier method with spermicide). The calendar method, withdrawal, or an IUD is NOT an acceptable method ?
- •6\.Except asthma disorder patient is judged to be in general good health to participate in trial based on medical history and physical examination as assessed by the Investigator
- •7\.Written informed consent signed by patient and willing to comply with the study procedure
Exclusion Criteria
- •1\.Pregnant or lactating female patient
- •2\.Hospitalization due to exacerbation of asthma within the previous 12 weeks preceding study entry (screening visit)
- •3\.Patient with clinically relevant upper respiratory tract infection 4 weeks prior or lower respiratory tract infection 8 weeks prior to the screening visit as judged by investigators
- •4\.Patient has a history of oral or parenteral steroids 4 weeks prior \& depot steroid 12 weeks prior to enrollment
- •5\.Patient who had received leukotriene antagonist and/ or Acebrophylline within 3 days of enrolment
- •6\.Patient with concurrent, previous or possible alcohol dependence, drug dependence or narcotic addiction as per DSM\-5
- •7\.Patient who have earlier participated in any other clinical trial within three months of screening
- •8\.Patient with a known history of clinically significant (including but not limited to) acute myocardial infarction, impaired hemodynamics, psychiatric, hepatic or/and renal disorders, Ambroxol allergy, GI disorders, phenylketonuria, pneumonia, pulmonary fibrotic disease, active tuberculosis, chronic obstructive pulmonary disease (COPD) or pneumothorax convulsion, arrhythmia, CAD, cardiac insufficiency and hyperthyroidism
- •9\.Patient with known history of Hypersensitivity to Acebrophylline or Montelukast or any other leukotriene antagonists or asprin or theophylline or any other xanthine derivative
- •10\.History of hepatitis B, hepatitis C or HIV infection
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Clinical study on JPF-16 Capsules in Sexual Dysfunction in FemalesHealth Condition 1: null- Female Sexual DysfunctionCTRI/2017/06/008791Chatarubhuj Pharmaceutical Co30
Completed
Phase 2
Clinical study on Ayuvita Forte Capsule in irregular periods with cysts in ovary.CTRI/2019/11/022183Welex Laboratories Pvt Ltd25
Completed
Not Applicable
A clinical trial to test the safety and effectiveness of Neuralzhein in management of memory loss related to age.Health Condition 1: F54- Psychological and behavioral factors associated with disorders or diseases classified elsewhereCTRI/2019/08/020711exxus Laboratories DBA OPUS PHARMA
Completed
Phase 3
To evaluate safety and performance of CREDENCEâ?¢ BtK Sirolimus Eluting BioResorbable Peripheral Scaffold System in subjects with Critical Limb Ischemiafollowing Percutaneous Transluminal Angioplasty of below the knee arteries.Health Condition 1: I739- Peripheral vascular disease, unspecifiedCTRI/2016/11/007473Meril Life Sciences Pvt Ltd30
Recruiting
Phase 1
A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with TheraSphere followed by immunotherapy (durvalumab and tremelimumab treatment)Hepatocellular CarcinomaMedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104Therapeutic area: Diseases [C] - Digestive System Diseases [C06]CTIS2023-508945-41-00Biocompatibles UK Limited107